Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Observational

ICCA-Based ICU Physiological State Space Monitor

NCT07773571 · tracked via the Priya Life Science China tracker
Phase
Observational
Started
2026-06-15
Last updated
2026-08-19

Condition(s) studied

Critical Illness

Investigational drug(s) / intervention(s)

Multidimensional ICU Physiological State and Trajectory Features

Multidimensional ICU Physiological State and Trajectory Features: The exposure of interest is the participant's multidimensional physiological state and trajectory derived from routinely collected ICU monitoring, laboratory, fluid, medication, organ-support, diagnostic, and demographic data. Daily state vectors will cover 10 physiological domains. Enhanced trajectory features will include state position, displacement, trajectory length, speed, acceleration, turning angle, curvature, local variability, lag-1 autocorrelation, recovery slope, and cross-domain coupling. The investigators will not assign any exposure, treatment, or clinical intervention.

Study summary

Critically ill patients can deteriorate rapidly across multiple organ systems. Most intensive care unit (ICU) risk tools rely on measurements collected at a single time point and may not fully capture how physiology evolves or how quickly a patient recovers from disturbance. This single-center retrospective observational study will use routinely collected data from the ICCA reporting database at Zhongshan Hospital, Fudan University to develop and internally validate a research prototype called the ICU Physiological State Space Monitor. Adult ICU admissions will be represented as daily state vectors across 10 physiological domains. The study will characterize each patient's position and movement in a multidimensional state space, identify high-risk regions and possible critical transitions, and quantify physiological resilience using trajectory features such as variability, autocorrelation, curvature, recovery slope, and cross-domain coupling. The primary validation outcome is a composite clinical deterioration event within 72 hours after an eligible index patient-day. The monitor is an analytic and visualization framework for retrospective research and will not be deployed for real-time clinical decision-making in this study.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age 18 years or older. * Admission to an ICU at Zhongshan Hospital, Fudan University between September 2021 and May 31, 2026, with a uniquely identifiable ICU encounter in the ICCA reporting-layer database. * ICU length of stay of at least 24 hours. * Availability of core variables from at least four physiological domains and at least one patient-day suitable for modeling. Exclusion Criteria: * Duplicate import of the same ICU encounter that cannot be reliably deduplicated. * Severe missingness, inconsistency, or irreconcilable error in key identifiers, ICU admission/discharge times, or core timestamps. * Test data, demonstration data, or records determined through data governance to be non-genuine patient records. * Inability to lock the primary source mapping for key variables, or overall data quality insufficient to support construction of the physiological state vector.

Primary outcome measure(s)

  • Composite Clinical Deterioration Within 72 Hours — Within 72 hours following each eligible index patient-day
    A binary composite outcome defined by the occurrence of at least one of the following events during the 72-hour window after an eligible index patient-day: ICU death; new initiation of invasive mechanical ventilation; new initiation of continuous renal replacement therapy (CRRT); new initiation of extracorporeal membrane oxygenation (ECMO); or a prespecified significant escalation in vasoactive medication support. A participant/index window meeting more than one component will be counted once for the composite outcome.

Trial sites (1)

FacilityCityRegionStatus
Zhongshan Hospital Shanghai Shanghai Municipality
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07773571 on ClinicalTrials.gov ↗ ← All trials in China